

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-17 (canceled)

18. (currently amended) A ~~[[The]]~~ pharmaceutical formulation ~~in as claimed in claim 10~~ wherein the unit dose form which is a “50 µg tablet” of active ingredient comprising ~~which comprises:~~ 0.0425-0.0575 mg levothyroxine sodium, 50-60 mg microcrystalline cellulose which has a mean particle size of less than 125 µm, 12-17 mg pregelatinised starch which is produced by subjecting moistened starch to mechanical pressure in order to rupture some or all of its starch granules and subsequent drying, 2-3 mg talc, 1-2 mg colloidal anhydrous silica₁ and 0.5-1.0 mg magnesium stearate.

19. (currently amended) A ~~[[The]]~~ pharmaceutical formulation ~~in as claimed in claim 10~~ wherein the unit dose form which is a “100 µg tablet” of active ingredient comprising ~~which comprises:~~ 0.085-0.115 mg levothyroxine sodium, 100-120 mg microcrystalline cellulose which has a mean particle size of less than 125 µm, 24-34 mg pregelatinised starch which is produced by subjecting moistened starch to mechanical pressure in order to rupture some or all of its starch granules and subsequent drying, 4-6 mg talc, 2-4 mg colloidal anhydrous silica₁ and 1-2 mg magnesium stearate.

Claims 20-34 (canceled)